直接作用型抗ウイルス薬の市場：タイプ、適応症、ルート、流通チャネル別-2025-2030年の世界予測

直接作用型抗ウイルス薬市場は、2023年に107億1,000万米ドルと評価され、2024年には121億8,000万米ドルに達すると予測され、CAGR 13.34％で成長し、2030年には257億6,000万米ドルに達すると予測されています。

直接作用型抗ウイルス薬（DAA）は、ウイルスの複製を直接阻害するように設計されており、特にウイルスの酵素機能を標的とし阻害します。これらの薬剤は、従来のインターフェロンベースの治療と比較して高い治癒率と少ない副作用を提供することにより、C型肝炎のようなウイルス感染症の治療状況に革命をもたらしています。DAAsの必要性は、ウイルス感染症の世界の重荷と、効果的で安全かつ迅速な治療オプションの必要性から生じています。その主な用途はヘルスケア産業で、病院、診療所、個々の患者を対象としており、医薬品開発に携わる製薬会社にも広がっています。最終用途の範囲は広大で、インドや中国などC型肝炎の罹患率が高い国々で市場が拡大しているほか、認知度の向上や診断法の改善により米国や欧州などの先進国市場でも拡大しています。

主な市場成長要因は、ウイルス感染率の増加、薬剤製剤の進歩、政府の支援策などです。併用療法や汎ジェノタイプ医薬品などのイノベーションは、市場拡大の潜在的機会を秘めています。これらの機会を捉えるための推奨事項としては、より広範な抗ウイルス薬の研究開発や戦略的提携への投資が挙げられます。しかし、高額な治療費、耐性変異、厳しい規制要件などの課題が大きな制約となっています。新興国における価格への敏感さや、医薬品へのアクセスに関する課題は、市場のハードルをさらに高めています。とはいえ、アクセスプログラムの拡大、ジェネリック医薬品の開発、インフルエンザやHIVのような幅広いウイルス遺伝子型や感染症に有効な医薬品の探索にはチャンスがあります。

革新的な分野としては、個別化医療、AIを活用した創薬、ドラッグデリバリーシステムの強化などが挙げられます。DAAにおけるマイクロバイオーム調節やナノテクノロジーといった新たな分野は、成長のための新たなフロンティアを開く可能性があります。DAA市場は、絶え間ない技術進化と規制当局の監視の目を特徴とし、依然として競争が激しいです。しかし、科学の進歩を戦略的に活用し、公衆衛生のニーズに合致した企業は、このダイナミックな環境で成功を収める可能性が高いです。これらの洞察は、DAA分野の複雑性をうまく乗り切ることができる企業にとって、DAA分野の成長と革新の両方の可能性があることを浮き彫りにしています。

市場力学：急速に進化する直接作用型抗ウイルス薬市場における重要な市場洞察の解明

直接作用型抗ウイルス薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業組織は十分な情報に基づいた投資決定、戦略的決定の精緻化、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肝細胞がんと肝硬変の有病率と発生率の増加
  • 新規直接作用型抗ウイルス薬の開発と上市の増加
  • 新興国における認知度の向上とヘルスケアインフラの改善
• 市場抑制要因
  • 直接作用型抗ウイルス薬の高コスト
• 市場機会
  • 直接作用型抗ウイルス薬に対する政府当局や社会医療団体からの支援の増加
  • 直接作用型抗ウイルス薬の入手可能性と組織間の戦略的提携
• 市場の課題
  • ブランド直接作用型抗ウイルス薬の特許切れ

ポーターの5つの力：直接作用型抗ウイルス薬市場をナビゲートする戦略ツール

ポーターの5つの力」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：直接作用型抗ウイルス薬市場における外部からの影響の把握

外部マクロ環境要因は、直接作用型抗ウイルス薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析直接作用型抗ウイルス薬市場における競合情勢の把握

直接作用型抗ウイルス薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス直接作用型抗ウイルス薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、直接作用型抗ウイルス薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨直接作用型抗ウイルス薬市場における成功への道筋を描く

直接作用型抗ウイルス薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝細胞がんおよび肝硬変の罹患率および発症率の増加
    • 新規直接作用型抗ウイルス薬の製品開発と発売の増加
    • 新興国における医療意識の高まりとヘルスケアインフラの改善
  • 抑制要因
    • 直接作用型抗ウイルス薬の高コスト
  • 機会
    • 直接作用型抗ウイルス薬に対する政府当局および社会ヘルスケア団体からの支援の拡大
    • 直接作用型抗ウイルス薬の入手可能性と組織間の戦略的連携
  • 課題
    • ブランド化された直接作用型抗ウイルス薬の特許満了
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 直接作用型抗ウイルス薬の市場：タイプ別

• NS3/4Aプロテアーゼ
• NS5Aタンパク質
• NS5B RNA依存性RNAポリメラーゼ

第7章 直接作用型抗ウイルス薬の市場適応症別

• C型肝炎ウイルス
• HIV感染/エイズ
• インフルエンザ
• 予防

第8章 直接作用型抗ウイルス薬の市場：ルート別

• 静脈内
• オーラル
• 皮下
• 話題

第9章 直接作用型抗ウイルス薬の市場：流通チャネル別

• 病院薬局
• オンラインドラッグストア
• 小売薬局

第10章 南北アメリカの直接作用型抗ウイルス薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の直接作用型抗ウイルス薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの直接作用型抗ウイルス薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Cipla Limited
• EVERSANA
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
• FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIRECT-ACTING ANTIVIRAL DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 63. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 67. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 136. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 152. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 156. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Direct-acting Antiviral Drug Market was valued at USD 10.71 billion in 2023, expected to reach USD 12.18 billion in 2024, and is projected to grow at a CAGR of 13.34%, to USD 25.76 billion by 2030.

Direct-acting antiviral (DAA) drugs are designed to directly interfere with the replication of viruses, particularly targeting and inhibiting their enzymatic functions. These drugs have revolutionized the treatment landscape for viral infections like hepatitis C by offering high cure rates and fewer side effects compared to traditional interferon-based therapies. The necessity for DAAs arises from the global burden of viral infections and the need for effective, safe, and quick therapeutic options. Their primary application is in the healthcare industry, serving hospitals, clinics, and individual patients, while extending to pharmaceutical companies involved in drug development. The end-use scope is vast, including larger markets in countries with high incidences of hepatitis C, such as India and China, and expanding in developed markets like the U.S. and Europe due to growing awareness and improved diagnostics.

Key market growth factors include increasing viral infection rates, advancements in drug formulations, and supportive government initiatives. Innovations such as combination therapies and pan-genotypic drugs hold potential opportunities for market expansion. Recommendations to seize these include investing in R&D and strategic collaborations for broader spectrum antiviral drugs. However, challenges such as high treatment costs, resistance mutations, and stringent regulatory requirements pose significant limitations. Price-sensitivity in emerging economies and challenges with drug accessibility further compound market hurdles. Nevertheless, opportunities lie in expanding access programs, developing generic versions, and exploring drugs effective against a broader range of viral genotypes and infections like influenza and HIV.

Innovative areas include personalized medicine, leveraging AI for drug discovery, and enhancing drug delivery systems. Emerging areas such as microbiome modulation and nanotechnology in DAAs could open new frontiers for growth. The DAA market remains highly competitive, characterized by continuous technological evolution and regulatory scrutiny. However, companies that strategically leverage scientific advancements and align with public health needs are likely to thrive in this dynamic environment. These insights highlight the potential for both growth and innovation within the DAA sector, for those who can navigate its complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Direct-acting Antiviral Drug Market

The Direct-acting Antiviral Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
  • Rising product development and launch of new direct-acting antiviral medicines
  • Growing awareness and improving healthcare infrastructure in emerging economies
• Market Restraints
  • High cost of direct-acting antiviral drugs
• Market Opportunities
  • Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
  • Availability of directly-acting antivirals medicines and strategic collaborations among organizations
• Market Challenges
  • Patent expiration of branded direct-acting antiviral

Porter's Five Forces: A Strategic Tool for Navigating the Direct-acting Antiviral Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Direct-acting Antiviral Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Direct-acting Antiviral Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Direct-acting Antiviral Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Direct-acting Antiviral Drug Market

A detailed market share analysis in the Direct-acting Antiviral Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Direct-acting Antiviral Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Direct-acting Antiviral Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Direct-acting Antiviral Drug Market

A strategic analysis of the Direct-acting Antiviral Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Direct-acting Antiviral Drug Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Cipla Limited, EVERSANA, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Direct-acting Antiviral Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.
• Based on Indication, market is studied across Hepatitis C Virus, HIV Infection/ AIDS, Influenza, and Prophylaxis.
• Based on Route, market is studied across Intravenous, Oral, Subcutaneous, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
    • 5.1.1.2. Rising product development and launch of new direct-acting antiviral medicines
    • 5.1.1.3. Growing awareness and improving healthcare infrastructure in emerging economies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of direct-acting antiviral drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
    • 5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations among organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Patent expiration of branded direct-acting antiviral
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Direct-acting Antiviral Drug Market, by Type

• 6.1. Introduction
• 6.2. NS3/4A Protease
• 6.3. NS5A Protein
• 6.4. NS5B RNA-Dependent RNA polymerase

7. Direct-acting Antiviral Drug Market, by Indication

• 7.1. Introduction
• 7.2. Hepatitis C Virus
• 7.3. HIV Infection/ AIDS
• 7.4. Influenza
• 7.5. Prophylaxis

8. Direct-acting Antiviral Drug Market, by Route

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Subcutaneous
• 8.5. Topical

9. Direct-acting Antiviral Drug Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Drug Store
• 9.4. Retail Pharmacy

10. Americas Direct-acting Antiviral Drug Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Direct-acting Antiviral Drug Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Boehringer Ingelheim International GmbH.
• 2. Bristol-Myers Squibb Company
• 3. Cipla Limited
• 4. EVERSANA
• 5. F. Hoffmann-La Roche Ltd.
• 6. Merck & Co., Inc.
• 7. Novartis AG
• 8. Pfizer Inc.
• 9. Takeda Pharmaceutical Company Limited
• 10. Viatris Inc.